Status: Recruiting
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at high risk of progression.
Participants needed: 102
Trial details
Phase: Phase 3Age: 18-100Biological sex: AllType: InterventionalSponsor: University Hospital, ToursUpdated: Jun 12, 2026Locations: 1
Eligibility criteria
Male and female 18 years and older who meet the American College of Rheumatology... [+6]
Known diagnosis of significant respiratory disorders (asthma, tuberculosis, aspe... [+14]